Bolt Biotherapeutics (NASDAQ:BOLT) COO Grant Yonehiro Sells 6,850 Shares of Stock

by · The Markets Daily

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) COO Grant Yonehiro sold 6,850 shares of the business’s stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $22,194.00. Following the sale, the chief operating officer directly owned 17,269 shares of the company’s stock, valued at approximately $55,951.56. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

  • On Thursday, September 17th, Grant Yonehiro sold 4,909 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.32, for a total value of $16,297.88.
  • On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.77, for a total value of $5,342.09.

Bolt Biotherapeutics Trading Up 0.8%

Shares of Bolt Biotherapeutics stock traded up $0.03 during trading on Monday, reaching $3.59. 22,454 shares of the company were exchanged, compared to its average volume of 27,365. The business has a 50-day moving average price of $3.84 and a 200-day moving average price of $4.29. The firm has a market capitalization of $6.93 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. Bolt Biotherapeutics, Inc. has a twelve month low of $3.10 and a twelve month high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Sell-side analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in shares of Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares during the period. T3 Companies LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $208,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in Bolt Biotherapeutics during the 2nd quarter worth approximately $19,250. Institutional investors and hedge funds own 86.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bolt Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $14.50.

View Our Latest Stock Analysis on BOLT

About Bolt Biotherapeutics

(Get Free Report)

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.

Featured Stories